Upstream / Downstream
Explore pathways related to this product.
Our U.S. Offices Will Be Closing Early
Our U.S. offices will be closing early on November 24th at 6:00 PM EST.
Find answers on our FAQs page.
PTM information and tools available.
IGF-I Receptor alpha Antibody #3022
This product is discontinued
Gallery: IGF-I Receptor alpha Antibody #3022
IGF-I Receptor beta Antibody detects endogenous levels of IGF-IR beta. It does not cross-react with insulin receptor.
Polyclonal antibodies are produced by immunizing animals with a synthetic peptide corresponding to the carboxy-terminal residues of human IGF-IR beta. Antibodies are purified by protein A and peptide affinity chromatography.
Type I insulin-like growth factor receptor (IGF-IR) is a transmembrane receptor tyrosine kinase that is widely expressed in many cell lines and cell types within fetal and postnatal tissues (1-3). Receptor autophosphorylation follows binding of the IGF-I and IGF-II ligands. Three tyrosine residues within the kinase domain (Tyr1131, Tyr1135, and Tyr1136) are the earliest major autophosphorylation sites (4). Phosphorylation of these three tyrosine residues is necessary for kinase activation (5,6). Insulin receptors (IRs) share significant structural and functional similarity with IGF-I receptors, including the presence of an equivalent tyrosine cluster (Tyr1146/1150/1151) within the kinase domain activation loop. Tyrosine autophosphorylation of IRs is one of the earliest cellular responses to insulin stimulation (7). Autophosphorylation begins with phosphorylation at Tyr1146 and either Tyr1150 or Tyr1151, while full kinase activation requires triple tyrosine phosphorylation (8).
For Research Use Only. Not For Use In Diagnostic Procedures. Cell Signaling Technology® is a trademark of Cell Signaling Technology, Inc.